Eli Lilly and Company
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All LLYD.BA news ›Is Eli Lilly Stock a Buy Right Now?
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next. Eli Lilly (LLY -0.73%) is expanding access at lower…
Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds. The…
Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
Lilly rose 6.6% last week as Nvidia fell 6.6%. Coincidence? The post Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point appeared first on Investor's Business Daily. BREAKING: AI Futures Rebound With Meta, SpaceX,…
Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
Goldman Sachs upgrades CoreWeave to buy from neutral Goldman said CoreWeave shares are undervalued and that investors should buy the dip. "We upgrade CoreWeave from Neutral to Buy with 73% upside to ...
Is Eli Lilly Stock Too Dependent On Two Drugs?
Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly’s (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for…
Metis TechBio, Eli Lilly Sign USD 1.1 Billion Drug Delivery Collaboration Deal
Bengaluru: Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to USD 1.1 billion to research and develop tissue-specific drug delivery technologies. The Chinese biotech will…
Eli Lilly signs delivery-technology deal with Chinese AI biotech Metis Techbio
Senior Drug Product Filling Specialist Faglig rådgiver til ATMP Danmark Senior Drug Substance Scientist Associate Market Access Director – European Markets Nordic Head of Commercial Excellence Associate Market Access Director –…
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
Oct 19 (Reuters) - Hong Kong-listed Metis TechBio on Monday said it has entered a collaboration agreement with Eli Lilly worth up to $1.1 billion for the research and development of tissue-specific drug delivery…
European Union Regulators Recommend Approval For Eli Lilly Weight Loss Pill
The European Medicines Agency’s committee recommended approval of Eli Lilly’s (LLY) weight-loss pill Foundayo on Friday, Reuters reports. It is the second oral obesity drug to get the agency’s backing, and Novo Nordisk’s Wegovy pill was…
Eli Lilly and Company $LLY Shares Bought by Foguth Wealth Management LLC.
Posted by Defense World Staff on Oct 20th, 2026 Get Our Latest Research Report on Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
fool.com24
-
marketscreener.com24
-
theglobeandmail.com18
-
gurufocus.com15
-
seekingalpha.com14
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.